- Home
- TECX vs ARCT Comparison
TECX vs ARCT Comparison
Compare TECX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- ARCT
- Stock Information
- Founded
- TECX 2019
- ARCT 2013
- Country
- TECX United States
- ARCT United States
- Employees
- TECX N/A
- ARCT N/A
- Industry
- TECX
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- TECX
- ARCT Health Care
- Exchange
- TECX Nasdaq
- ARCT Nasdaq
- Market Cap
- TECX 334.4M
- ARCT 298.3M
- IPO Year
- TECX 2018
- ARCT N/A
- Fundamental
- Price
- TECX $21.51
- ARCT $12.53
- Analyst Decision
- TECX Buy
- ARCT Strong Buy
- Analyst Count
- TECX 6
- ARCT 8
- Target Price
- TECX $79.20
- ARCT $52.33
- AVG Volume (30 Days)
- TECX 172.8K
- ARCT 450.8K
- Earning Date
- TECX 05-08-2025
- ARCT 05-12-2025
- Dividend Yield
- TECX N/A
- ARCT N/A
- EPS Growth
- TECX N/A
- ARCT N/A
- EPS
- TECX N/A
- ARCT N/A
- Revenue
- TECX N/A
- ARCT $143,680,000.00
- Revenue This Year
- TECX N/A
- ARCT N/A
- Revenue Next Year
- TECX N/A
- ARCT $42.36
- P/E Ratio
- TECX N/A
- ARCT N/A
- Revenue Growth
- TECX N/A
- ARCT 15.38
- 52 Week Low
- TECX $13.70
- ARCT $8.04
- 52 Week High
- TECX $61.07
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- TECX 51.42
- ARCT 54.31
- Support Level
- TECX $21.20
- ARCT $11.51
- Resistance Level
- TECX $22.75
- ARCT $13.00
- Average True Range (ATR)
- TECX 1.43
- ARCT 0.98
- MACD
- TECX 0.01
- ARCT 0.08
- Stochastic Oscillator
- TECX 41.32
- ARCT 57.74
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.